Luc Dehaspe

Luc Dehaspe

Auto-generated profile, based on publicly available information

Luc Dehaspe

Genomics Core, KU Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
LBLieselot Buedts
Lieselot Buedts
IWIwona Wlodarska
Iwona Wlodarska
JFJulio Finalet-Ferreiro
Julio Finalet-Ferreiro
OGOlivier Gheysens
Olivier Gheysens
LDLuc Dehaspe
Luc Dehaspe
PVPeter Vandenberghe
Peter Vandenberghe
The low abundance of Hodgkin/Reed-Sternberg (HRS) cells in lymph node biopsies in classical Hodgkin lymphoma (cHL) complicates the analysis of somatic genetic alterations in HRS cells. As circulating cell-free DNA (cfDNA) contains circulating tumor DNA (ctDNA) from HRS cells, we prospectively collected cfDNA from 177 patients with newly diagnosed, mostly early-stage cHL in a monocentric study at Leuven, Belgium (n = 59) and the multicentric BREACH study by Lymphoma Study Association (n = 118). To catalog the patterns and frequencies of genomic copy number aberrations (CNAs), cfDNA was sequenced at low coverage (0.26×), and data were analyzed with ichorCNA to yield read depth-based copy number profiles and estimated clonal fractions in cfDNA. At diagnosis, the cfDNA concentration, estimated clonal fraction, and ctDNA concentration were significantly higher in cHL cases than controls. More than 90% of patients exhibited CNAs in cfDNA. The most frequent gains encompassed 2p16 (69%), 5p14 (50%), 12q13 (50%), 9p24 (50%), 5q (44%), 17q (43%), 2q (41%). Losses mostly affected 13q (57%), 6q25-q27 (55%), 4q35 (50%), 11q23 (44%), 8p21 (43%). In addition, we identified loss of 3p13-p26 and of 12q21-q24 and gain of 15q21-q26 as novel recurrent CNAs in cHL. At diagnosis, ctDNA concentration was associated with advanced disease, male sex, extensive nodal disease, elevated erythrocyte sedimentation rate, metabolic tumor volume, and HRS cell burden. CNAs and ctDNA rapidly diminished upon treatment initiation, and persistence of CNAs was associated with increased probability of relapse. This study endorses the development of ctDNA as gateway to the HRS genome and substrate for early disease response evaluation.

23 October 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
LLLiesbeth Lenaerts
Liesbeth Lenaerts
NBN. Brison
N. Brison
MNM. Neofytou
M. Neofytou
HCH. Che
H. Che
LDL. Dehaspe
L. Dehaspe
FAFrédéric Amant
Frédéric Amant
Background: Early cancer diagnosis might significantly improve survival rates. As circulating tumor (ctDNA) carries cancer-specific modifications, it has great potential as a non-invasive biomarker for detection of incipient tumors.